Skip to content

Can-Fite on go with mid-stage study of Piclidenoson for COVID-19

August 31, 2020

The FDA has signed off on a Phase 2 clinical trial evaluating Can-Fite BioPharma’s (NYSEMKT:CANF) lead drug Piclidenoson for the potential treatment of COVID-19.

Enrollment will now proceed with the 40-subject 28-day study.

The primary endpoints are safety, the proportion of patients alive and free of respiratory failure at day 29 and the proportion of patients discharged from the hospital at day 29 without the need for supplemental oxygen.

The stock has been underperforming the Nasdaq Composite this year so positive results should give it a lift.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: